By: National Cancer Centre Singapore From: medicalxpress.com A team of clinicians and scientists from the National Cancer Centre Singapore (NCCS), Singapore General Hospital (SGH) and A*STAR’s Genome Institute of Singapore (GIS) has identified a novel method to treat triple-negative breast cancer (TNBC). They discovered that cancer cells switch between different cell states and are able to change from being less …
Lutris Pharma Initiates Part Two of its Phase 1/2 Trial of LUT014 To Treat Radiation Dermatitis in Breast Cancer Patients
From: prnewswire.com Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing dose limiting side effects, today announced that, based on the compelling results observed in part one, it has initiated part two of its phase 1/2 trial of lead compound, LUT014, a topically applied, novel B-Raf inhibitor, for the treatment of radiation-induced dermatitis (RD) in …
Next Oncology Expands Phase I Program with Virginia Cancer Specialists Partnership
Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, has entered into a joint venture with Virginia Cancer Specialists (VCS). Dr. Alex Spira of VCS sought to expand the clinic’s Phase I and developmental therapeutics cancer research program and bring the latest in new agents and anticancer treatments to its Research Institute. NEXT Oncology has relationships …
Defence Therapeutics embark on next stage of breast cancer treatment development
From: healtheuropa.eu In a groundbreaking development, pioneering biotechnology company Defence Therapeutics has announced today it will be performing the final necessary studies before entering a Phase 1 trial for its innovative AccuTOX breast cancer treatment. AccuTOX is one of Defence Therapeutics‘ premier candidates for effective breast cancer treatment and is comprised of the company’s cutting-edge AccumTM technology platform, which was …
Clinical Challenges: When to Start End-of-Life Care in Metastatic Breast Cancer
By: Leah Lawrence From: medpagetoday.com Breast cancer remains the second leading cause of cancer death among women in the U.S. Although treatments for metastatic breast cancer — whether a new diagnosis or recurrent disease — have improved in recent years, metastatic disease remains incurable, explained Dawn L. Hershman, MD, MS, director of breast oncology at the Herbert Irving Comprehensive Cancer …
Clinical dilemmas in breast cancer patients solved by newly approved PET imaging agent
Source: Society of Nuclear Medicine and Molecular Imaging From: news-medical.net A non-invasive, patient-friendly imaging technique can help physicians make treatment decisions for breast cancer patients when diagnostic dilemmas arise. The 18F-FES PET scan-;approved by the U.S. Food and Drug Administration in 2020-;was shown to solve 87 percent of dilemmas, providing physicians with information for personalized treatment decision-making. This research was …
Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival
Source: Inbiomotion From: prnewswire.com – Level 1 evidence from the MAF Test® analyses of the NSABP-B34 landmark clinical trial confirmed clinical utility of the MAF Test® for selection of early-stage breast cancer patients that benefit from adjuvant clodronate treatment to prevent metastasis – Data published in Journal of National Cancer Institute, Cancer Spectrum – MAF-negative status of patients who were …
Radionuclide therapy a promising option to treat HER2 breast cancer
From: europeanpharmaceuticalreview.com The radionuclide treatment combines radioactive iodine therapy with single-domain antibodies to target the HER2 antigen. A Phase I trial has found that radionuclide treatment may offer new therapeutic options for human epidermal growth factor receptor type 2 (HER2)-positive breast cancer. The treatment combines radioactive iodine therapy with single-domain antibodies that target the HER2 antigen to destroy cancer cells. …
Novian Health Gains FDA Breakthrough Designation for Novilase Breast Therapy
Groundbreaking laser therapy offers alternative to surgery for breast cancer Novian Health Inc. has been granted Breakthrough Device designation from the U.S. Food and Drug Administration for its Novilase®Interstitial Laser System and its proposed indication for use: the focal destruction of malignant breast tumors in adult women who seek a breast conserving procedure. The FDA’s Breakthrough Device program supports the …
Tyme Technologies Begins Cancer Metabolism-Based Therapy Trial in Breast Cancer Patients
By: Staff Reporter From: precisiononcologynews.com Tyme Technologies said on Monday it has dosed the first patient in its Phase II OASIS trial of SM-88 in previously treated metastatic hormone receptor (HR)-positive HER2-negative breast cancer patients. The investigator-initiated study at Georgetown University will initially enroll 30 patients with metastatic HR-positive HER2-negative breast cancer who have previously received at least two lines …